Introduction
A rare form of childhood lung tumor known as a pulmonary blastoma originates in the chest, either in the lung tissue (pulmonary) or in the tissue that covers the lungs and the lining of the pleura, which is sometimes termed the chest cavity. Pulmonary blastomas are more common in boys than in girls.
Tumors begin to form when healthy cells undergo mutations and expand uncontrollably, forming a mass known as a tumor. A tumor can be either malignant or benign. A malignant tumor is cancerous and has the potential to grow and spread to other areas of the body. If a tumor is benign, it means it can grow but will not spread to other parts of the body.
What Are the Risk Factors?
A person's likelihood of acquiring a tumor is increased by everything that can be classified as a risk factor. Even though risk factors frequently play a role in the development of tumors, the vast majority of them do not directly cause tumors. While some people exposed to several risk factors will never acquire a tumor, others not exposed to any known risk factors will have the following reasons.
-
A genetic mutation of the DICER1 RNase-IIIb gene, also known as a germline mutation, is present in most patients with pulmonary blastoma .
-
Inherited mutations in a family are known as germline mutations, and they are passed down from one generation to the next in the family.
-
RNase-IIIb mutation from one of the parents.
-
Other cancers, such as cystic nephroma, cervical rhabdomyosarcoma, nasal chondromesenchymal hamartoma, ovarian stromal tumors, nodular thyroid hyperplasia, ciliary body medulloepithelioma, and pineoblastoma, have also been linked to the DICER1 syndrome.
What Is the Diagnostic Method?
-
Biopsy: A biopsy involves removing a small tissue sample for examination under a microscope. Other tests may indicate the presence of a tumor, but only a biopsy can confirm the presence of a tumor. Afterward, a pathologist, a physician who interprets laboratory tests and examines cells, tissues, and organs to diagnose disease, analyzes the specimen(s).
-
X-Ray: X-rays can generate an image of the internal body structures using a small amount of radiation.
-
Computed Tomography Scan (CT): Using X-rays captured from multiple angles, a CT scan produces images of the body's interior that display abnormalities or tumors. The extent of the tumor can be determined using a CT scan. If a chest X-ray reveals lung abnormalities, pulmonary blastoma will perform a CT scan.
-
Magnetic Resonance Imaging (MRI): MRI produces comprehensive images of the human body using magnetic fields to determine the extent of the tumor. An MRI is not as effective as a CT scan for detecting pulmonary blastoma within the chest, but it is frequently the most effective test for examining other areas of the body to determine if the tumor has spread.
-
Bone Scan: A radioactive tracer is used to examine the interior of the bones during a bone scan. There is insufficient radiation in the tracer to be deleterious. The tracer is administered through intravenous injection. It accumulates in regions of the bone and is detected by a specialized camera. Injured areas, such as those caused by a tumor, stand out in the image, whereas healthy bone appears darker.
What Are the Signs and Symptoms?
Depending on the child's age and the form of pulmonary blastoma, children with pulmonary blastoma exhibit two distinct sets of symptoms:
-
Respiratory Failure: Respiratory distress or difficulty breathing (dyspnea) can range from mild to severe. Large air pockets in the chest can inhibit normal respiration. The lung may contain massive air pockets (cysts) that compress the normal lung. Occasionally, air can escape cysts into the thoracic cavity (pneumothorax). These air pockets will be detected by a chest X-ray or computed tomography (CT) scan, and further investigation will result in their surgical removal.
-
Pneumonia: Typically, these symptoms are observed in children with pulmonary blastoma types II and III. They exhibit symptoms of pneumonia or another general illness, including cough, fever, difficulty breathing, fatigue, loss of energy, and decreased appetite.
-
Chest or abdominal pains.
-
Weight decline.
-
An X-ray of the thorax will reveal a problem that may resemble pneumonia (lung infection).
-
Chest or lung tumor.
Antibiotics are commonly administered to children for two to three weeks, but when pulmonary blastoma causes these symptoms, they do not typically resolve.
Which Are the Different Stages of the Condition?
-
Advanced PPB: It is diagnosed when the tumor has progressed beyond its initial site. Typically, this indicates that the tumor has migrated within the chest cavity or to the diaphragm, the thin muscle that lies beneath the lungs and heart and separates the chest from the abdomen. PPB can also travel to other organs through the bloodstream, such as the bones, liver, and brain.
-
Recurrent PPB: It refers to a tumor that has returned after treatment. Additional tests will be conducted to determine its severity if the condition returns. These examinations and scans frequently resemble those performed during the initial diagnosis.
What Is the Treatment Method?
-
Medications: The medications commonly used to treat pulmonary blastoma are the same or comparable to those used to treat more prevalent pediatric cancers. Even though pulmonary blastoma is uncommon, pediatric cancer specialists have experience with the use of these drugs. Their use in other children guides the use of these substances in children with pulmonary blastoma.
-
Radiation: Patients with pulmonary blastoma receive highly individualized radiation therapy. Radiation may be considered if there is a small area of the tumor that could not be removed by surgery and does not appear to be reduced in size with chemotherapy. As radiation can cause injury to lung tissue, the radiation oncology team limits the doses and locations of radiation therapy. When pulmonary blastoma has progressed to the brain, surgery followed by radiation therapy is often recommended.
-
Chemotherapy: A second potential treatment for pulmonary blastoma is high-dose chemotherapy followed by autologous stem cell transplantation. This comprehensive approach may be beneficial in cases where pulmonary blastoma has yet to be eliminated by more conventional therapy.
Conclusion
Pleuropulmonary blastoma is a malignancy characterized by high aggressiveness that predominantly affects children under the age of six. The diagnostic criteria for pleuropulmonary blastoma include the presence of a mass lesion, complete opacification of the hemithorax, the absence of calcification within the lesion, and no indications of invasion of the chest wall, erosion of the ribs, or extension into the spinal region. Pulmonary blastoma has been found to exhibit an association with DICER1 syndrome. Patients who have been diagnosed with malignancy need to have radical surgery, even in cases where there is evidence of microscopic residual disease
